journal

Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response

This Phase 1 proof‑of‑principle study shows that combining Vigil (a personalized tumor vaccine) with atezolizumab is safe and yields promising survival benefits in relapsed ovarian cancer, especially for BRCA wild‑type patients. Its impact lies in demonstrating a novel immunotherapy approach with real potential to improve outcomes, address immune resistance, and inform larger trials, potentially transforming treatment options for ovarian cancer.